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1. Introduction {#sec005}
===============

The use of bioprosthetic valves in surgical aortic valve replacement (AVR) has increased considerably during the last few decades \[[@pone.0233894.ref001]\], particularly in middle-aged patients, largely driven by patients' wish of avoiding lifelong anticoagulation. However, bioprosthesis degenerates, requiring reoperation, which remains a relatively high risk. The evolution of transcatheter aortic valve replacement (TAVR) has enabled a safe and feasible alternative, the transcatheter valve-in-valve (VIV) procedure, which is less invasive than conventional redo surgery and has comparable outcomes \[[@pone.0233894.ref002]--[@pone.0233894.ref006]\]. Considering the possibility of future transcatheter VIV, the trend of increasing use of bioprostheses in surgical AVR is likely to persist, and the need of aortic VIV is expected to grow exponentially in the future.

Balloon-expandable valve (BEV) and self-expanding valve (SEV) are the two major types of transcatheter heart valves (THVs). These two THV types are different in valve height, implantation depth, relative position of the valve and the annulus, radial force, deployment mechanism, and valve geometry and therefore may result in different outcomes and rates of complication, such as postprocedural transvalvular pressure gradient, conduction block, or paravalvular leak (PVL). Currently, there is no randomized study comparing the two types of THVs, and only few observational studies have been published, with the observation that SEV was associated with better postprocedural hemodynamic performance but higher rates of postprocedural permanent pacemaker (PPM) implantation and aortic regurgitation \[[@pone.0233894.ref007], [@pone.0233894.ref008]\]. However, the most recent publication is a single-center study with limited number of patients and thus may not represent the whole population well \[[@pone.0233894.ref007]\]. Large cohort studies exist but are relatively outdated \[[@pone.0233894.ref008], [@pone.0233894.ref009]\]. Hence, a meta-analysis of the most recent studies is warranted to guide physicians in selecting the optimal device for VIV candidates.

2. Material and methods {#sec006}
=======================

We conducted this systematic review and meta-analysis in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. A PRISMA checklist used for this review is provided in the **[S1 Table](#pone.0233894.s002){ref-type="supplementary-material"}**. The study has been registered on PROSPERO (CRD42018111178).

2.1. Literature search {#sec007}
----------------------

We performed a computer search of the Medline, PubMed, Embase, and Cochrane databases using the following keywords: "transcatheter", "aortic", "valve", "failed", "failing", "degenerated", "degeneration", "degenerative", "deterioration", and "valve in valve". The detailed search strategy is provided in the **[S1 Appendix](#pone.0233894.s001){ref-type="supplementary-material"}**. All relevant studies published until April 2020 were identified. Review articles and meta-analyses were screened for additional studies from the cited references. The processes of searching and reviewing were independently performed by 2 evaluators (H.-A. Lee and S.-W. Chen). Discrepancies were discussed to achieve a consensus.

2.2. Study selection {#sec008}
--------------------

Inclusion criteria were as follows: (1) original article with full-length content available in English, (2) at least 10 patients who underwent aortic VIV procedures for failed surgical aortic bioprosthesis using either Edwards Lifesciences or Medtronic THVs were enrolled, and (3) results of patients who underwent aortic VIV procedures with BEV or SEV were reported. Studies were excluded if they met any of the following conditions: (1) study population overlapped with another study, including subgroup studies of a main study; (2) devices other than Medtronic valves (Medtronic, Minneapolis, MN) and Edwards Lifesciences valves (Edwards Lifesciences, Irvine, CA) were used; and (3) VIV for failed THVs. If studies were suspected of involving an overlapping cohort, only data of the most recent publication were included for analysis.

2.3. Data extraction {#sec009}
--------------------

Data extracted were characteristics of the enrolled studies and characteristics of patients reported, including baseline information and outcomes. Study-level characteristics included year of publication, study period, location of the study conducted, number of hospitals, and number of patients included. Baseline patient-level information included age, Society of Thoracic Surgery (STS) score, European System for Cardiac Operative Risk Evaluation (EuroSCORE) II, logistic EuroSCORE, comorbidities, left ventricular ejection fraction, devices used, and characteristics of previous bioprosthesis. Thirty-day and 1-year outcomes were extracted, including death of any cause, cardiovascular death, stroke, coronary artery obstruction, major vascular complications, PPM implantation, major or life-threatening bleeding, acute kidney injury, second valve required, conversion to traditional surgery, and hemodynamics of the implanted valves.

2.4. Quality assessment {#sec010}
-----------------------

The Newcastle--Ottawa Scale (NOS) \[[@pone.0233894.ref010]\] was used to assess the quality of included studies, with scores ranging from 0 (lowest quality) to 8 (highest quality). Two reviewers (H.-A. Lee and S.-W. Chen) assessed the scores of each study separately; disagreements between the 2 reviewers were discussed until a consensus was achieved.

2.5. Statistical analysis {#sec011}
-------------------------

The estimates of primary and secondary outcomes derived from individual studies for each arm (Medtronic or Edwards Lifesciences valves) were pooled using the random-effects model. In contrast to the fixed-effects model, a random-effects model enables the true underlying effect to vary among individual studies. *I*^2^ values \>25%, \>50%, and \>75% were considered to represent low, moderate, and high heterogeneity across the studies, respectively \[[@pone.0233894.ref011]\]. The pooled estimates between the BEV and SEV were compared using the mixed-effects model. In a further subgroup analysis, we compared outcomes between the Evolut R (Medtronic) and Sapien 3 (Edwards Lifesciences) valves. Statistical significance was set at *P* \< 0.05 with a two-tailed test. Data were analyzed using the software Comprehensive Meta-Analysis (version 3.3; Biostat, Inc., Englewood, NJ, USA).

3. Results {#sec012}
==========

3.1. Literature search {#sec013}
----------------------

The literature screened, excluded, reviewed, and included for analysis is illustrated in **[Fig 1](#pone.0233894.g001){ref-type="fig"}**. Of the 398 articles yielded by computer search, 293 were excluded after titles and abstracts were screened. Full texts of 105 articles were reviewed to evaluate eligibility; of them, 5 were excluded because they were meta-analysis or review articles, 12 because their case numbers were \<10, 9 because they included duplicated cohorts, and 52 because they did not report outcomes of patients who underwent VIV with BEV or SEV. Hence, 27 studies were included for the final quantitative meta-analysis \[[@pone.0233894.ref007], [@pone.0233894.ref008], [@pone.0233894.ref012]--[@pone.0233894.ref036]\]. All 27 studies were observational. Five of the studies reported outcomes of both BEV and SEV, while the other 22 studies enrolled only 1 of the 2 types of THV. Basic information of the 27 studies is shown in **[Table 1](#pone.0233894.t001){ref-type="table"}**. Three studies derived from Valve-In-Valve International Database were included because each of them has data that was not reported in the other articles. For items that were reported by more than 1 of the studies, only those reported by the latest publication were included in our analysis. Quality assessment was performed using the NOS, with scores of the 27 studies ranging 5--9 points **([S2 Table](#pone.0233894.s003){ref-type="supplementary-material"})**.

![Flow diagram depicting study selection process.](pone.0233894.g001){#pone.0233894.g001}

10.1371/journal.pone.0233894.t001

###### Study data.

![](pone.0233894.t001){#pone.0233894.t001g}

  First author                               Year   Valve types   Study type      Locations/country   No. of centers   study period   Patient number
  ------------------------------------------ ------ ------------- --------------- ------------------- ---------------- -------------- ----------------
  Woitek \[[@pone.0233894.ref034]\]          2020   BEV, SEV      Single center   Germany             1                2006--2017     146
  Ribeiro \[[@pone.0233894.ref036]\]         2018   BEV, SEV      Multi-center    Global              135              2007--2014     1324
  Ochiai \[[@pone.0233894.ref007]\]          2018   BEV, SEV      Single center   California, USA     1                2012--2017     74
  Dvir \[[@pone.0233894.ref008]\]            2014   BEV, SEV      Multi-center    Global              55               2007--2013     459
  Ihlberg \[[@pone.0233894.ref022]\]         2013   BEV, SEV      Multi-center    Nordic              11               2008--2012     45
  Stankowski \[[@pone.0233894.ref029]\]      2020   SEV           Single center   Germany             1                2003--2018     68
  Pascual \[[@pone.0233894.ref033]\]         2019   SEV           Single center   Spain               1                2012--2017     45
  Schwerg \[[@pone.0233894.ref013]\]         2018   SEV           Single center   Germany             1                2013--2017     26
  Scholtz \[[@pone.0233894.ref014]\]         2018   SEV           Single center   Germany             1                2009--2016     37
  Sang \[[@pone.0233894.ref031]\]            2018   SEV           Single center   Michigan, USA       1                2014--1016     22
  Deeb \[[@pone.0233894.ref017]\]            2017   SEV           Multi-center    USA                 NA               2013--2015     227
  Chhatriwalla \[[@pone.0233894.ref018]\]    2017   SEV           Single center   Michigan, USA       9                NA             12
  Duncan \[[@pone.0233894.ref020]\]          2015   SEV           Single center   UK                  1                2009--2014     22
  Ong \[[@pone.0233894.ref023]\]             2012   SEV           Multi-center    Germany             3                NA             18
  Linke \[[@pone.0233894.ref024]\]           2012   SEV           Single center   Germany             1                NA             27
  Bedogni \[[@pone.0233894.ref027]\]         2011   SEV           Multi-center    Italy               8                NA             25
  Murdoch \[[@pone.0233894.ref030]\]         2020   BEV           Multi-center    Global              46               2012--2015     339
  Stankowski \[[@pone.0233894.ref032]\]      2019   BEV           Single center   Germany             1                2010--2018     27
  Seiffert \[[@pone.0233894.ref012]\]        2018   BEV           Multi-center    Global              NA               NA             514
  Webb \[[@pone.0233894.ref015]\]            2017   BEV           Multi-center    Worldwide           34               2012--2014     365
  Nielsen-Kudsk \[[@pone.0233894.ref016]\]   2017   BEV           Single center   Denmark             1                2015--2017     10
  Ye \[[@pone.0233894.ref019]\]              2015   BEV           Single center   Canada              1                2007--2013     42
  Bapat \[[@pone.0233894.ref021]\]           2014   BEV           Single center   UK                  1                2010--2014     10
  Seiffert \[[@pone.0233894.ref035]\]        2012   BEV           Single center   Germany             1                2008--2011     11
  Bapat \[[@pone.0233894.ref025]\]           2012   BEV           Single center   UK                  1                2009--2011     23
  Pasic \[[@pone.0233894.ref026]\]           2011   BEV           Single center   Germany             1                NA             14
  Kempfert \[[@pone.0233894.ref028]\]        2010   BEV           Single center   Germany             1                2007--2009     11

Basic information of studies included in the meta-analysis.

BEV, balloon-expandable valve; SEV, self-expanding valve

3.2. Baseline and procedural characteristics {#sec014}
--------------------------------------------

**[Table 2](#pone.0233894.t002){ref-type="table"}** shows the pooled baseline and procedural characteristics of all patients in the 27 included studies. A total of 2,269 and 1,671 patients in the BEV and SEV groups were included. Mean age (78.0 ± 1.6 years in BEV vs. 75.6 ± 10.0 years in SEV), STS score (9.0 ± 2.5 in BEV vs. 9.2 ± 2.2 in SEV), left ventricular ejection fraction (50.0 ± 2.7% in BEV vs. 51.1 ± 3.0% in SEV), and other baseline echocardiographic parameters appeared to be similar between the 2 groups. The proportion of small degenerated surgical bioprostheses (≤21mm) appeared slightly lower in BEV (25.6%) than in SEV (30.7%) groups; however, the proportion of small THVs (≤23 mm) used was much higher in the BEV group (67.5%) than in the SEV group (26.9%). Transfemoral access was more frequently used in the SEV group (95%) than in the BEV group (61.3%).

10.1371/journal.pone.0233894.t002

###### Baseline and procedural characteristics of patients (number of included studies = 27).

![](pone.0233894.t002){#pone.0233894.t002g}

                             BEV (Edwards)   SEV (Medtronic)         
  -------------------------- --------------- ----------------- ----- -------------
  Age (year)                 1087            78.0 ± 1.6        788   75.6 ± 10.0
  Male (%)                   1097            63.3%             751   55.3%
  Log EuroSCORE              730             21.7 ± 9.9        586   26.2 ± 3.4
  EuroSCORE II               53              19.6 ± 5.7        188   11.3 ± 2.9
  STS score                  1087            9.0 ± 2.5         678   9.2 ± 2.2
  CAD (%)                    491             65.2%             431   61.7%
  Prior stroke (%)           1065            13.7%             666   11.7%
  Prior Afib (%)             392             46.2%             467   42.0%
  Prior PPM (%)              943             17.2%             377   22.5%
  PAD (%)                    1050            23.7%             674   22.7%
  CKD (%)                    1009            37.4%             674   34.3%
  AR ≥moderate (%)           648             43.4%             509   54.0%
  Bioprosthesis age (year)   732             10.5 ± 1.6        657   9.9 ± 1.3
  Stented valve (%)          1078            84.2%             867   75.1%
  Stentless valve (%)        809             13.6%             867   19.6%
  Bioprosthesis size (%)     1097                              746   
      ≤21 mm                                 25.6%                   30.7%
      21--24.9 mm                            40.4%                   37.9%
      ≥25 mm                                 31.4%                   28.9%
      Unknown                                2.3%                    3.2%
  Mode of failure (%)                                                
      AS                     1126            45.8%             632   53.2%
      AR                     1126            28.0%             620   27.3%
      Mix                    1116            26.6%             583   21.8%
  LVEF (%)                   829             50.0 ± 2.7        527   51.1 ± 3.0
  AV area (cm^2^)            699             0.90 ± 0.08       671   0.95 ± 0.09
  AVA index (cm^2^/m^2^)     900             0.53 ± 0.06       213   0.55
  Max PG (mmHg)              341             62.6 ± 8.5        423   61.0 ± 9.2
  Mean PG (mmHg)             1022            34.6 ± 3.8        754   36.0 ± 4.4
  Fluoroscopic time (min)    436             18.3 ± 3.4        92    19.6 ± 9.8
  THV size ≤23 mm (%)        1299            67.5%             490   26.9%
  TF access (%)              1076            68.5%             561   95.0%

Abbreviations: Afib, atrial fibrillation; AR, aortic regurgitation; AS, aortic stenosis; AV, aortic valve; AVA, aortic valve area; CAD, coronary artery disease; CKD, chronic kidney disease; LVEF, left ventricular ejection fraction; PAD, peripheral artery disease; PG, pressure gradient; PPM, permanent pacemaker; PVL, paravalvular leak; STS, Society of Thoracic Surgery; TF, transfemoral; THV, transcatheter heart valve.

3.3. Clinical and echocardiographic outcomes {#sec015}
--------------------------------------------

The event rates of all-cause mortality, cardiovascular death, and stroke at 30 days did not differ significantly between the BEV and SEV groups (**[Fig 2A](#pone.0233894.g002){ref-type="fig"}**). However, BEV was associated with significantly lower rates of major vascular complications (4.7% vs. 8.7%; *P* = 0.012), PPM implantation (3.8% vs. 12%; *P* \< 0.001), and second valve requirement (2.9% vs. 6.2%; *P* = 0.004). One-year all-cause mortality and stroke rates were similar between the 2 groups (**[Fig 2B](#pone.0233894.g002){ref-type="fig"}**).

![Forest plot comparing 30-day (A) and 1-year (B) clinical outcomes between BEV and SEV. BEV = balloon-expandable valve; SEV = self-expanding valve.](pone.0233894.g002){#pone.0233894.g002}

Regarding echocardiographic outcomes, SEV was associated with better hemodynamic performance than BEV, with significantly larger postoperative effective orifice area (EOA) at 30 days (1.53 cm^2^ vs. 1.23 cm^2^; *P* \< 0.001) and 1 year (1.55 cm^2^ vs. 1.22 cm^2^; *P* \< 0.001; **[Fig 3A and 3C](#pone.0233894.g003){ref-type="fig"}**) and lower maximal and mean pressure gradients at 1 year (respectively, 23.0 mm Hg vs. 33.3 mm Hg, *P* = 0.001; and 13 mm Hg vs. 18.4 mm Hg, *P* = 0.002; **[Fig 3C](#pone.0233894.g003){ref-type="fig"}**).

![Forest plot comparing echocardiographic outcomes between BEV and SEV.\
Thirty-day continuous outcomes (A), 30-day binary outcomes (B), and 1-year continuous outcomes (C) of BEV and SEV were compared.](pone.0233894.g003){#pone.0233894.g003}

3.4. Subgroup analysis for newer devices {#sec016}
----------------------------------------

We also compared the outcomes with the Sapien 3 (Edwards Lifesciences) and Evolut R (Medtronic) valves. These are the newest generation of the 2 types of THVs with published data available for analyses. Although no statistical significance was found, Evolut R seemed to be associated with a lower mean pressure gradient than Sapien 3 (**[Fig 4](#pone.0233894.g004){ref-type="fig"}**).

![Subgroup analysis comparing 30-day outcomes of Sapien 3 and Evolut R valves for 30-day continuous outcomes (A) and 30-day binary outcomes (B).](pone.0233894.g004){#pone.0233894.g004}

4. Discussion {#sec017}
=============

4.1. Major findings {#sec018}
-------------------

With nearly 4000 patients included, the present meta-analysis is the largest sample used for comparing BEV and SEV outcomes in patients with failed aortic valve bioprostheses thus far. Our major findings were as follows: (1) all-cause mortality and cardiovascular death did not differ significantly between the 2 groups; (2) BEV was associated with lower rates of new PPM implantation and major vascular complications; and (3) SEV was associated with larger postprocedural EOA than BEV, both at 30 days and at 1 year.

4.2. New PPM implantation {#sec019}
-------------------------

SEV use is an independent risk factor for PPM implantation in the overall TAVR population \[[@pone.0233894.ref037]--[@pone.0233894.ref039]\]. However, previous aortic valve procedures, including surgical AVR, seemed to be protective against post-TAVR PPM implantation \[[@pone.0233894.ref037], [@pone.0233894.ref039]\], possibly because the previously implanted bioprosthesis restricted the expansion of the THV. In the present meta-analysis, the pooled PPM implantation rate after SEV implantation was 10.7%, which is nearly 3-fold that in the BEV group (3.6%; *P* \< 0.001). In other words, even under the potential protection of the old bioprosthesis, SEV is still associated with significantly higher risk of postprocedural PPM implantation. This finding is consistent with previous studies focusing on aortic VIV procedure \[[@pone.0233894.ref008], [@pone.0233894.ref009]\].

4.3. EOA {#sec020}
--------

A major concern of the aortic VIV procedure is the relatively small postprocedural aortic valve area and high transvalvular pressure gradient, mainly resulting from restricted expansion of the THVs by the old valves. Several publications, including studies using an *in vitro* model \[[@pone.0233894.ref040], [@pone.0233894.ref041]\], large cohort studies \[[@pone.0233894.ref008], [@pone.0233894.ref009]\], and propensity-matched analysis \[[@pone.0233894.ref007]\], reported that SEV was associated with larger postprocedural aortic valve area and lower transvalvular gradient than BEV after aortic VIV procedures. The current meta-analysis further supported these findings in the largest sample size to date.

In the SEV we analyzed, the functioning part is positioned above the aortic annulus (i.e., the "supra-annular design," which is thought to lessen the detrimental impact on postprocedural EOA by the old valve). The theory was supported by a study using *in vitro* model in which researchers found that when the CoreValve was positioned deeper than normal, the leaflets were more constrained, and EOA decreased; and when the SAPIEN was placed more supra-annularly, the leaflets expanded more completely, and postprocedural EOA became larger \[[@pone.0233894.ref041]\].

One may argue that the higher percentage of small THVs (≤23mm) used in the BEV group alone can explain the smaller postprocedural EOA in BEV. However, the proportions of small degenerated surgical bioprostheses (≤21mm) were similar between the 2 groups (**[Table 2](#pone.0233894.t002){ref-type="table"}**), so why were small THVs more often used in the BEV group? We believe that the supra-annular design of Medtronic SEV allows a relatively larger size, while the intra-annular design of Edward BEV results in marked leaflet distortion if the size is too large \[[@pone.0233894.ref041]\]. According to the ViV Aortic app, for 19 or 21mm degenerated bioprostheses, a 23mm Medtronic THV, or a 20mm Edward THV is suggested. A study using the Valve-in-Valve International Data Registry also found that elevated postprocedural pressure gradient were more common after BEV-VIV implantation than after SEV-VIV; for small surgical valves (internal diameter \< 20mm) and intermediate-sized valves (internal diameter ≥20mm and \<23mm) \[[@pone.0233894.ref008]\].

Insufficient EOA and elevated transvalvular pressure gradient not only diminish patients' physical activity and quality of life but also predict early structural valve degeneration in bioprosthetic heart valves \[[@pone.0233894.ref042]\]. In addition, incomplete THV expansion itself leads to localized high stress within the leaflets, which may accelerate valve degeneration \[[@pone.0233894.ref043]\].

4.4. SEV versus BEV {#sec021}
-------------------

According to the present meta-analysis, SEV was associated with significantly better postprocedural EOA, which can reduce the risk of patient--prosthesis mismatch and improve quality of life, particularly in patients with larger body size or whose old bioprosthesis is small. Lower transvalvular gradient and better THV expansion may also lead to superior durability of the THV, which is important in patients with life expectancy of 20 years or longer. Nevertheless, higher EOA and lower gradient of SEV did not translate in to lower mortality. Moreover, SEV was associated with higher rates of postprocedural PPM implantation, which is detrimental to late outcome \[[@pone.0233894.ref037], [@pone.0233894.ref044]\].

Therefore, CoreValve may be beneficial in patients whose previous surgical valve is small and those at high risk of patient--prosthesis mismatch. However, Edwards valves may be preferred to Medtronic valves for patients with adequate surgical valve size, particularly those who are prone to encounter postprocedural PPM implantation or PVL, including patients who are older \[[@pone.0233894.ref037]\] and those who have prior conduction disturbances \[[@pone.0233894.ref038]\] or a prolonged PR interval \[[@pone.0233894.ref045]\]. For every transcatheter aortic VIV candidate, particularly younger patients, the valve selection decision should be made carefully after thorough consideration of device characteristics and patient condition and preference, as well as detailed explanation and discussion.

4.5. Study limitations {#sec022}
----------------------

The study has several limitations. First, this meta-analysis was based on published articles; therefore, data quality and availability are limited. Second, owing to a lack of randomized controlled trials in this area, all studies included were observational, so our results can only be interpreted as "associations," rather than as "causations." However, the absence of randomized studies warrants the present meta-analysis to help in optimizing device selection. Third, THV devices continue advancing rapidly, so the outcomes of the present study may differ from those of the newest device.

5. Conclusion {#sec023}
=============

The present systematic review and meta-analysis found that for patients who underwent transcatheter aortic VIV, SEV was associated with significantly larger postprocedural EOA but higher rates of PPM implantation and PVL of moderate or higher degree. These findings provide valuable information in guiding proper management for patients with degenerated aortic bioprostheses.

Supporting information {#sec024}
======================

###### Detailed search strategy.

(DOCX)

###### 

Click here for additional data file.
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(DOC)
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Click here for additional data file.

###### Newcastle-Ottawa Scale quality assessment of included studies.

(DOCX)

###### 

Click here for additional data file.
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1\. Why is there such a large difference between the % of baseline \>=moderate MR between the 2 groups (25.5% vs 68.3%)

2\. Could the higher number of stented valves in the BEV group explain the higher PVL after the procedures?

3\. Given that transfemoral access is the most common modality why were there only 67.8% in the BEV group? Especially given that alternate access is associated with higher periprocedural complication rates.

4\. Higher EOA and Lower gradients have been shown in prior studies with SEV, although they did not translate into lower mortality with SEV compared to BEV. Can the authors elaborate on that in their discussion?

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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The following is a point-by-point response to reviewers comments.

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

2\. We noticed that the search of your systematic review was last performed in October 2018. Please ensure that the search is up to date and that the systematic review/meta-analysis includes any new studies published since then

Response: We have updated the search to April 2020.

Reviewer \#1: This is a very interesting review and meta-analysis of VIV-treatment. However, there are some points to discuss:

1\. Comparison of EOA between SEV and BEV:

It should be better explained why the EOA of SEV is bigger than BEV. The used BEV-Size was smaller than the SEV-Sizes (THV size ≤ 23mm 65,7% vs 31,7%), this alone can explain the difference. How was the gradient-/EOA- difference in treated small surgical bioprosthesis (\<21mm), are there data available?

Response: Thanks for the great question. Regarding gradient-/EOA- difference in treated small surgical bioprostheses, a study using the Valve-in-Valve International Data Registry found that elevated postprocedural pressure gradient (mean ≥ 20mmHg) were more common with BEVs in comparison with SEVs; for small surgical valves (internal diameter \[ID\] \< 20mm), 41.2% vs 23.4% (P = .04) and for intermediate-sized valves (≥20 and \< 23), 35.8% vs 19.4% (P = .01), respectively \[1\](eFigure 2C). Moreover, 11.8% of Edwards SAPIEN VIV procedures performed inside small bioprosthesis had very high postprocedural gradients (mean ≥ 40mmHg), while no cases of CoreValve VIV procedures resulted in very high gradients (P = 0.005, eFigure 2D).

We believe that the supra-annular design of Medtronic SEV allows a relatively larger size, while an intra-annular design of Edwards BEV results in marked leaflet distortion if the size is too large. This can explain why the ViV Aortic app suggests 20mm Edwards THVs inside19 or 21mm degenerated bioprosthesis, but 23mm Medtronic THVs inside same-sized bioprostheses.

In conclusion, the supra-annular design of Medtronic CoreValve allows better expansion of the leaflets, and allows a relatively larger sized THV to be inserted inside a small bioprosthesis, hence results in better EOA/gradient.

We have added the above explanation and citation in the revised manuscript.

2\. There was a recent publication about measuring error of measured echo gradients in intra annular and supra annular valves (Abbas AE and Pibarot P, CCI 2019). Are there data about invasive measured gradients after VIV available.

Response: Abbas et. al. demonstrated the catheterization/echocardiography discordance after native TAVR and after Valve-in-Valve TAVR\[2\]. The echocardiography mean gradient is significantly higher than catheterization gradient after both procedures.

In all the studies we reviewed, only 1 reported postprocedural catheterization gradients\[3\]. The postprocedural mean echocardiographic gradient and mean invasive gradient were 22.8 and 13.6 mmHg, respectively (P \< 0.001).

3\. For a recommendation which valve should be used in which situation, the coronary access possibility after VIV should be discussed, as there are differences between BEV and SEV.

Response: Yes, the coronary access possibility after VIV is a very important concern. Allali et. al. reported their experience of coronary intervention after TAVR\[4\]. However, the aim of the current meta-analysis is to collect evidences and analyze. Since we did not find sufficient data regarding coronary-related outcomes after ViV to perform meta-analysis, we did not include this point in our manuscript. Nevertheless, if you consider the point suitable for our article, we would like to add it in our manuscript according to your suggestion.

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

Reviewer \#2: it is a very important subject that the authors have performed a metanalysis on given the sparse RCT data comparing these 2 valves. Some questions that need to be answered:

1\. Why is there such a large difference between the % of baseline \>=moderate MR between the 2 groups (25.5% vs 68.3%)

Response: In the original analysis, very few study reported the percentage of baseline ≥moderate AR. A single study of high or low % made a large difference in the results. After collecting more data, the % of baseline ≥moderate AR was 43.4% and 54.0 in the BEV and SEV groups, respectively. However, it should be noted that only a small portion of studies reported baseline ≥moderate AR, so the result does not well represent the whole population.

2\. Could the higher number of stented valves in the BEV group explain the higher PVL after the procedures?

Response: In studies comparing outcomes following VIV inside stentless versus stented bioprostheses, stentless bioprostheses appeared to be related to higher PVL than stented bioprostheses\[5, 6\]. Hence, the higher percentage of stentless valves in the SEV group in our study could contribute to the higher rates of postprocedural PVL.

However, in the revised manuscript, after updating research with more recent data included in the meta-analysis, the difference of postprocedural PVL between BEV and SEV groups was no longer significant.

3\. Given that transfemoral access is the most common modality why were there only 67.8% in the BEV group? Especially given that alternate access is associated with higher periprocedural complication rates.

Response: The proportion of transfemoral (TF) access reported by the two largest registry regarding Edwards VIV, VIVID Registry and PARTNER 2 VIV Registry, were 66.7% and 75.4%, respectively\[7, 8\]. In VIVID Registry, the TF ratio of Sapien XT was only 58.5%. Although nowadays approximately 5% of TAVR candidates require a non-femoral access, in the earlier era, 10\~20% of patients require non-femoral access because previous-generation devices had larger profile. Transapical access, which could only be performed using BEV, was the first-developed non-femoral access, and had been the most commonly used non-femoral access for quite a few years. This may explain the lower percentage of TF access in BEV group, especially in earlier era. After updating the search to April, 2020, the TF ratio of BEV group slightly increased to 68.5%

4\. Higher EOA and Lower gradients have been shown in prior studies with SEV, although they did not translate into lower mortality with SEV compared to BEV. Can the authors elaborate on that in their discussion?

Response: Thanks for the suggestion. We have discussed EOA and gradients in sections 4.3 and 4.4 of discussion in the original manuscript. We also added a sentence in the first paragraph of section 4.4 to emphasize that higher EOA and lower gradient of SEV did not translate into lower mortality. If there is any further suggestion from the reviewer, we will be glad to revise our manuscript accordingly.
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